Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients
Aim: To investigate aromatase inhibitor‐induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. Methods: Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 ± 9.9 years) receiving non‐steroidal aromatase inhibitor (...
Saved in:
| Published in | The Journal of obstetrics and gynaecology research Vol. 33; no. 5; pp. 696 - 699 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Melbourne, Australia
Blackwell Publishing Asia
01.10.2007
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1341-8076 1447-0756 |
| DOI | 10.1111/j.1447-0756.2007.00634.x |
Cover
| Abstract | Aim: To investigate aromatase inhibitor‐induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Methods: Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 ± 9.9 years) receiving non‐steroidal aromatase inhibitor (AI; anastrozole, 1 mg daily) only and 10 such patients (mean age, 65.0 ± 5.1 years) receiving AI + bisphosphonate (risedronate sodium, 2.5 mg daily) for 6 months. All of the subjects had undergone surgical resection and had positive estrogen receptor tumor status. Age, age at menopause, years since menopause, height, weight, and body mass index (Wt/Ht2) were recorded. Lumbar spine (L2–4) bone mineral density (BMD), T‐, and Z‐scores were assessed on dual‐energy X‐ray absorptiometry before and after therapy.
Results: In the AI‐only group BMD, T‐, and Z‐scores significantly decreased from the baseline during the 6‐month therapy period (P < 0.05). Mean decreases in L2–4 BMD and Z‐score were 2.5% and 3.0%, respectively. In the AI + bisphosphonate group, however, BMD, T‐, and Z‐scores significantly increased from the baseline values (P < 0.01). Mean increases in L2–4 BMD and Z‐score were 4.5% and 3.3%, respectively.
Conclusion: AI carries a potential risk of bone mineral loss despite the short therapy duration. Bisphosphonate has a preventive effect on this loss. |
|---|---|
| AbstractList | To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 +/- 9.9 years) receiving non-steroidal aromatase inhibitor (AI; anastrozole, 1 mg daily) only and 10 such patients (mean age, 65.0 +/- 5.1 years) receiving AI + bisphosphonate (risedronate sodium, 2.5 mg daily) for 6 months. All of the subjects had undergone surgical resection and had positive estrogen receptor tumor status. Age, age at menopause, years since menopause, height, weight, and body mass index (Wt/Ht(2)) were recorded. Lumbar spine (L2-4) bone mineral density (BMD), T-, and Z-scores were assessed on dual-energy X-ray absorptiometry before and after therapy.
In the AI-only group BMD, T-, and Z-scores significantly decreased from the baseline during the 6-month therapy period (P < 0.05). Mean decreases in L2-4 BMD and Z-score were 2.5% and 3.0%, respectively. In the AI + bisphosphonate group, however, BMD, T-, and Z-scores significantly increased from the baseline values (P < 0.01). Mean increases in L2-4 BMD and Z-score were 4.5% and 3.3%, respectively.
AI carries a potential risk of bone mineral loss despite the short therapy duration. Bisphosphonate has a preventive effect on this loss. Aim: To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. Methods: Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 plus or minus 9.9 years) receiving non-steroidal aromatase inhibitor (AI; anastrozole, 1 mg daily) only and 10 such patients (mean age, 65.0 plus or minus 5.1 years) receiving AI + bisphosphonate (risedronate sodium, 2.5 mg daily) for 6 months. All of the subjects had undergone surgical resection and had positive estrogen receptor tumor status. Age, age at menopause, years since menopause, height, weight, and body mass index (Wt-Ht super(2)) were recorded. Lumbar spine (L2-4) bone mineral density (BMD), T-, and Z-scores were assessed on dual-energy X-ray absorptiometry before and after therapy. Results: In the AI-only group BMD, T-, and Z-scores significantly decreased from the baseline during the 6-month therapy period (P < 0.05). Mean decreases in L2-4 BMD and Z-score were 2.5% and 3.0%, respectively. In the AI + bisphosphonate group, however, BMD, T-, and Z-scores significantly increased from the baseline values (P < 0.01). Mean increases in L2-4 BMD and Z-score were 4.5% and 3.3%, respectively. Conclusion: AI carries a potential risk of bone mineral loss despite the short therapy duration. Bisphosphonate has a preventive effect on this loss. To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.AIMTo investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 +/- 9.9 years) receiving non-steroidal aromatase inhibitor (AI; anastrozole, 1 mg daily) only and 10 such patients (mean age, 65.0 +/- 5.1 years) receiving AI + bisphosphonate (risedronate sodium, 2.5 mg daily) for 6 months. All of the subjects had undergone surgical resection and had positive estrogen receptor tumor status. Age, age at menopause, years since menopause, height, weight, and body mass index (Wt/Ht(2)) were recorded. Lumbar spine (L2-4) bone mineral density (BMD), T-, and Z-scores were assessed on dual-energy X-ray absorptiometry before and after therapy.METHODSSubjects were 17 postmenopausal breast cancer patients (mean age, 63.3 +/- 9.9 years) receiving non-steroidal aromatase inhibitor (AI; anastrozole, 1 mg daily) only and 10 such patients (mean age, 65.0 +/- 5.1 years) receiving AI + bisphosphonate (risedronate sodium, 2.5 mg daily) for 6 months. All of the subjects had undergone surgical resection and had positive estrogen receptor tumor status. Age, age at menopause, years since menopause, height, weight, and body mass index (Wt/Ht(2)) were recorded. Lumbar spine (L2-4) bone mineral density (BMD), T-, and Z-scores were assessed on dual-energy X-ray absorptiometry before and after therapy.In the AI-only group BMD, T-, and Z-scores significantly decreased from the baseline during the 6-month therapy period (P < 0.05). Mean decreases in L2-4 BMD and Z-score were 2.5% and 3.0%, respectively. In the AI + bisphosphonate group, however, BMD, T-, and Z-scores significantly increased from the baseline values (P < 0.01). Mean increases in L2-4 BMD and Z-score were 4.5% and 3.3%, respectively.RESULTSIn the AI-only group BMD, T-, and Z-scores significantly decreased from the baseline during the 6-month therapy period (P < 0.05). Mean decreases in L2-4 BMD and Z-score were 2.5% and 3.0%, respectively. In the AI + bisphosphonate group, however, BMD, T-, and Z-scores significantly increased from the baseline values (P < 0.01). Mean increases in L2-4 BMD and Z-score were 4.5% and 3.3%, respectively.AI carries a potential risk of bone mineral loss despite the short therapy duration. Bisphosphonate has a preventive effect on this loss.CONCLUSIONAI carries a potential risk of bone mineral loss despite the short therapy duration. Bisphosphonate has a preventive effect on this loss. Aim: To investigate aromatase inhibitor‐induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. Methods: Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 ± 9.9 years) receiving non‐steroidal aromatase inhibitor (AI; anastrozole, 1 mg daily) only and 10 such patients (mean age, 65.0 ± 5.1 years) receiving AI + bisphosphonate (risedronate sodium, 2.5 mg daily) for 6 months. All of the subjects had undergone surgical resection and had positive estrogen receptor tumor status. Age, age at menopause, years since menopause, height, weight, and body mass index (Wt/Ht2) were recorded. Lumbar spine (L2–4) bone mineral density (BMD), T‐, and Z‐scores were assessed on dual‐energy X‐ray absorptiometry before and after therapy. Results: In the AI‐only group BMD, T‐, and Z‐scores significantly decreased from the baseline during the 6‐month therapy period (P < 0.05). Mean decreases in L2–4 BMD and Z‐score were 2.5% and 3.0%, respectively. In the AI + bisphosphonate group, however, BMD, T‐, and Z‐scores significantly increased from the baseline values (P < 0.01). Mean increases in L2–4 BMD and Z‐score were 4.5% and 3.3%, respectively. Conclusion: AI carries a potential risk of bone mineral loss despite the short therapy duration. Bisphosphonate has a preventive effect on this loss. Aim: To investigate aromatase inhibitor‐induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. Methods: Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 ± 9.9 years) receiving non‐steroidal aromatase inhibitor (AI; anastrozole, 1 mg daily) only and 10 such patients (mean age, 65.0 ± 5.1 years) receiving AI + bisphosphonate (risedronate sodium, 2.5 mg daily) for 6 months. All of the subjects had undergone surgical resection and had positive estrogen receptor tumor status. Age, age at menopause, years since menopause, height, weight, and body mass index (Wt/Ht 2 ) were recorded. Lumbar spine (L2–4) bone mineral density (BMD), T‐, and Z‐scores were assessed on dual‐energy X‐ray absorptiometry before and after therapy. Results: In the AI‐only group BMD, T‐, and Z‐scores significantly decreased from the baseline during the 6‐month therapy period ( P < 0.05). Mean decreases in L2–4 BMD and Z‐score were 2.5% and 3.0%, respectively. In the AI + bisphosphonate group, however, BMD, T‐, and Z‐scores significantly increased from the baseline values ( P < 0.01). Mean increases in L2–4 BMD and Z‐score were 4.5% and 3.3%, respectively. Conclusion: AI carries a potential risk of bone mineral loss despite the short therapy duration. Bisphosphonate has a preventive effect on this loss. |
| Author | Kosha, Shoichiro Rai, Yoshiaki Douchi, Tsutomu Iwamoto, Ichiro Yonehara, Yukie Sagara, Yoshiatsu |
| Author_xml | – sequence: 1 givenname: Yukie surname: Yonehara fullname: Yonehara, Yukie organization: Department of Obstetrics and Gynecology, Kagoshima University Medical and Dental Hospital, Sakuragaoka, and – sequence: 2 givenname: Ichiro surname: Iwamoto fullname: Iwamoto, Ichiro organization: Department of Obstetrics and Gynecology, Kagoshima University Medical and Dental Hospital, Sakuragaoka, and – sequence: 3 givenname: Shoichiro surname: Kosha fullname: Kosha, Shoichiro organization: Sagara Hospital, Tainokuchi, Kagoshima, Japan – sequence: 4 givenname: Yoshiaki surname: Rai fullname: Rai, Yoshiaki organization: Sagara Hospital, Tainokuchi, Kagoshima, Japan – sequence: 5 givenname: Yoshiatsu surname: Sagara fullname: Sagara, Yoshiatsu organization: Sagara Hospital, Tainokuchi, Kagoshima, Japan – sequence: 6 givenname: Tsutomu surname: Douchi fullname: Douchi, Tsutomu email: tomy@m3.kufm.kagoshima-u.ac.jp organization: Department of Obstetrics and Gynecology, Kagoshima University Medical and Dental Hospital, Sakuragaoka, and |
| BackLink | https://cir.nii.ac.jp/crid/1570854175468590848$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/17845332$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1u1DAUhSNURH_gFZAXiF0GO_FfJIRUVZ0pqKIbEIiN5Tg3qofECbYDM6_AU-NMyizYFEtxrpTvnBudc56duMFBliGCVySdN9sVoVTkWDC-KjAWK4x5SVe7J9nZ8cNJmktKcokFP83OQ9hiTERF5LPslAhJWVkWZ9nvSz_0OuoAyLp7W9s4-Ny6ZjLQoDptRb114HWHuiEEpF2DbAxo9PATXLSDQ_Ue1TaM98P8OB0B6SZpbIheHwDr0DiE2IMbRj2FZFV70CEio50Bj8aEJa_wPHva6i7Ai4f3RfZ5ff3p6ia_vdu8v7q8zQ1jlOa8MAwDqTkQySjBrS5xBaQQtGhBEiK5bCtcMNHiBuqClaSpiKmMKWkjWkLLi-z14jv64ccEIareBgNdpx0MU1BcFpxUhD8KFpjJikmRwJcP4FT30KjR2177vfobcwLeLYDxKUUPrTI2HtJJIdlOEazmXtVWzfWpuT4196oOvapdMpD_GBx3PC59u0h_2Q72_61TH-42aUjyV4vcWZv-er4JE3iOXjDKJauwpDJh-YKl3mF33KL9d8VFKZj68nGj1t9wRdc3a_W1_AOt6NWO |
| CitedBy_id | crossref_primary_10_1097_GCO_0b013e3283240745 crossref_primary_10_1016_j_arcmed_2014_10_007 crossref_primary_10_1007_s12282_009_0135_7 crossref_primary_10_1002_14651858_CD013451_pub2 crossref_primary_10_1016_j_ecl_2011_05_008 crossref_primary_10_1016_j_jmig_2009_05_009 crossref_primary_10_1080_14656566_2024_2340712 crossref_primary_10_1111_j_1742_7843_2008_00337_x crossref_primary_10_1111_cen_12549 crossref_primary_10_2217_ahe_10_42 crossref_primary_10_1002_pds_1486 crossref_primary_10_1097_01_med_0000436195_10599_dd crossref_primary_10_1016_j_eurger_2017_06_004 crossref_primary_10_1158_1078_0432_CCR_10_1595 |
| Cites_doi | 10.3816/CBC.2005.s.002 10.1016/S0029-7844(97)00124-5 10.1001/jama.295.23.joc60074 10.1002/cncr.11745 10.1200/jco.2006.24.18_suppl.511 10.1158/1078-0432.CCR-04-2187 10.1053/j.seminoncol.2006.03.022 10.1016/j.ejca.2006.07.005 10.3816/CBC.2000.s.002 10.3816/CBC.2005.s.006 10.1200/JCO.2005.07.097 10.1053/j.seminoncol.2004.09.023 10.1056/NEJMra022219 10.1016/j.ejca.2005.10.028 10.3816/CBC.2005.s.003 10.1016/S0378-5122(00)00094-3 10.1006/gyno.1998.5023 10.1200/JCO.2005.02.7102 10.1016/j.breast.2004.09.005 10.1210/jc.2005-2827 |
| ContentType | Journal Article |
| DBID | BSCLL RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7X8 |
| DOI | 10.1111/j.1447-0756.2007.00634.x |
| DatabaseName | Istex CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Calcium & Calcified Tissue Abstracts MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1447-0756 |
| EndPage | 699 |
| ExternalDocumentID | 17845332 10_1111_j_1447_0756_2007_00634_x JOG634 10019949577 ark_67375_WNG_FZ094FHF_X |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AEYWJ AFWVQ AGQPQ AGYGG ALVPJ RYH AAYXX AGHNM CITATION CGR CUY CVF ECM EIF NPM 7QP AAMMB AEFGJ AGXDD AIDQK AIDYY 7X8 |
| ID | FETCH-LOGICAL-c5544-62c50e1b6e185410fa309e12742fe811868f90257f0deb2531d91c9cc34d7f143 |
| IEDL.DBID | DR2 |
| ISSN | 1341-8076 |
| IngestDate | Fri Jul 11 16:54:44 EDT 2025 Fri Jul 11 01:18:52 EDT 2025 Wed Feb 19 01:45:40 EST 2025 Tue Jul 01 02:30:25 EDT 2025 Thu Apr 24 23:44:09 EDT 2025 Wed Jan 22 16:53:55 EST 2025 Thu Jun 26 21:37:30 EDT 2025 Wed Oct 30 09:54:37 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5544-62c50e1b6e185410fa309e12742fe811868f90257f0deb2531d91c9cc34d7f143 |
| Notes | ark:/67375/WNG-FZ094FHF-X istex:48536EFD827E753F7403786D402A6163266EF944 ArticleID:JOG634 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 17845332 |
| PQID | 20589587 |
| PQPubID | 23462 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_68261916 proquest_miscellaneous_20589587 pubmed_primary_17845332 crossref_citationtrail_10_1111_j_1447_0756_2007_00634_x crossref_primary_10_1111_j_1447_0756_2007_00634_x wiley_primary_10_1111_j_1447_0756_2007_00634_x_JOG634 nii_cinii_1570854175468590848 istex_primary_ark_67375_WNG_FZ094FHF_X |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2007 |
| PublicationDateYYYYMMDD | 2007-10-01 |
| PublicationDate_xml | – month: 10 year: 2007 text: October 2007 |
| PublicationDecade | 2000 |
| PublicationPlace | Melbourne, Australia |
| PublicationPlace_xml | – name: Melbourne, Australia – name: Australia |
| PublicationTitle | The Journal of obstetrics and gynaecology research |
| PublicationTitleAlternate | J Obstet Gynaecol Res |
| PublicationTitle_FL | J Obstet Gynaecol Res |
| PublicationYear | 2007 |
| Publisher | Blackwell Publishing Asia |
| Publisher_xml | – name: Blackwell Publishing Asia |
| References | Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006; 33 (2 Suppl 7): 13-17. Theriault RL. Strategies to prevent chemotherapy-induced bone loss in women with breast cancer. Clin Breast Cancer 2005; 5 (Suppl 2): S63-S70. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone, or in Combination) trial efficacy and safety update analysis. Cancer 2003; 98: 1802-1810. Geisler J, Lonning PE. Aromatase inhibition: Translation into a successful therapeutic approach. Clin Cancer Res 2005; 11: 2809-2818. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-828. Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005; 5: S35-S40. Vogel VG, Costantino JP, Wickerham DL et al. Effect of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741. Johannessen DC, Engan T, Di Salle E et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 1997; 3: 1101-1108. Paterson AH. Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer 2005; 5 (Suppl 2): S41-S45. Mortimer JE, Urban JH. Long-term toxicity of selective estrogen-receptor modulators and antiaromatase agents. Oncology 2003; 17: 652-659. Geisler J, Lonning PE, Krag LE et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomized, placebo-controlled study. Eur J Cancer 2006; 42: 2968-2975. Coleman RE. Hormone- and chemotherapy induced bone loss in breast cancer. Oncology 2004; 18 (Suppl 2): 16-20. Coleman RE; ATAC Trialist's Group. Effect of anastrozole on bone mineral density: 5-year results from the arimidex, tamoxifen, alone or in combination ATAC trial. J Clin Oncol 2006; 24 (Suppl 18S): Abstract 511. Douchi T, Kosha S, Kan R, Nakamura S, Oki T, Nagata Y. Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents. Obstet Gynecol 1997; 90: 12-15. Coleman RE, Banks LM, Girgis SI et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES): 2 year bone mineral density (BMD) and bone biomarker data. Breast Cancer Res Treat 2005; 94 (Suppl 1): S233. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69: 220-225. Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005; 5 (Suppl 2): S35-S40. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982; 59: 680-686. Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer endocrine therapy. Semin Oncol 2004; 31: 23-30. McCloskey E. Effect of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42: 1044-1051. Aapro MS. Long-term implication of bone loss in breast cancer. Breast 2004; 13: S29-S37. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: Mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-629. Eng-Wong J, Reynolds JC, Venzon D et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006; 91: 3941-3946. Miller WR, Dixon JM. Antiaromatase agents: Preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000; 1 (Suppl): S9-S14. Douchi T, Yamamoto S, Oki T et al. The effects of physical exercise on body fat distribution and bone mineral density in postmenopausal women. Maturitas 2000; 35: 25-30. Lonning PE, Geisler J, Krag LE et al. Effect of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarker, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23: 5126-5137. 1997; 90 1982; 59 2004; 31 2006; 91 2006; 42 2003; 348 2004; 18 2006; 24 2006; 33 2000; 35 2004; 13 2005; 5 2006; 295 2003; 17 2000; 1 2005; 94 1997; 3 2005; 11 2005; 23 2003; 98 2007; 25 1998; 69 e_1_2_5_26_2 Coleman RE (e_1_2_5_5_2) 2004; 18 e_1_2_5_27_2 e_1_2_5_24_2 e_1_2_5_25_2 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_20_2 e_1_2_5_21_2 Coleman RE; ATAC Trialist's Group. (e_1_2_5_8_2) 2006; 24 Johannessen DC (e_1_2_5_11_2) 1997; 3 e_1_2_5_14_2 e_1_2_5_13_2 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_6_2 e_1_2_5_12_2 e_1_2_5_4_2 e_1_2_5_3_2 e_1_2_5_2_2 e_1_2_5_18_2 Mortimer JE (e_1_2_5_17_2) 2003; 17 Judd HL (e_1_2_5_19_2) 1982; 59 Coleman RE (e_1_2_5_15_2) 2005; 94 |
| References_xml | – reference: Miller WR, Dixon JM. Antiaromatase agents: Preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000; 1 (Suppl): S9-S14. – reference: McCloskey E. Effect of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42: 1044-1051. – reference: Theriault RL. Strategies to prevent chemotherapy-induced bone loss in women with breast cancer. Clin Breast Cancer 2005; 5 (Suppl 2): S63-S70. – reference: Geisler J, Lonning PE. Aromatase inhibition: Translation into a successful therapeutic approach. Clin Cancer Res 2005; 11: 2809-2818. – reference: Mortimer JE, Urban JH. Long-term toxicity of selective estrogen-receptor modulators and antiaromatase agents. Oncology 2003; 17: 652-659. – reference: Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone, or in Combination) trial efficacy and safety update analysis. Cancer 2003; 98: 1802-1810. – reference: Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982; 59: 680-686. – reference: Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: Mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-629. – reference: Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005; 5 (Suppl 2): S35-S40. – reference: Douchi T, Kosha S, Kan R, Nakamura S, Oki T, Nagata Y. Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents. Obstet Gynecol 1997; 90: 12-15. – reference: Coleman RE. Hormone- and chemotherapy induced bone loss in breast cancer. Oncology 2004; 18 (Suppl 2): 16-20. – reference: Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69: 220-225. – reference: Vogel VG, Costantino JP, Wickerham DL et al. Effect of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741. – reference: Johannessen DC, Engan T, Di Salle E et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 1997; 3: 1101-1108. – reference: Geisler J, Lonning PE, Krag LE et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomized, placebo-controlled study. Eur J Cancer 2006; 42: 2968-2975. – reference: Lonning PE, Geisler J, Krag LE et al. Effect of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarker, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23: 5126-5137. – reference: Douchi T, Yamamoto S, Oki T et al. The effects of physical exercise on body fat distribution and bone mineral density in postmenopausal women. Maturitas 2000; 35: 25-30. – reference: Aapro MS. Long-term implication of bone loss in breast cancer. Breast 2004; 13: S29-S37. – reference: Eng-Wong J, Reynolds JC, Venzon D et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006; 91: 3941-3946. – reference: Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer endocrine therapy. Semin Oncol 2004; 31: 23-30. – reference: Coleman RE; ATAC Trialist's Group. Effect of anastrozole on bone mineral density: 5-year results from the arimidex, tamoxifen, alone or in combination ATAC trial. J Clin Oncol 2006; 24 (Suppl 18S): Abstract 511. – reference: Coleman RE, Banks LM, Girgis SI et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES): 2 year bone mineral density (BMD) and bone biomarker data. Breast Cancer Res Treat 2005; 94 (Suppl 1): S233. – reference: Paterson AH. Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer 2005; 5 (Suppl 2): S41-S45. – reference: Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006; 33 (2 Suppl 7): 13-17. – reference: Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005; 5: S35-S40. – reference: Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-828. – volume: 13 start-page: S29 year: 2004 end-page: S37 article-title: Long‐term implication of bone loss in breast cancer publication-title: Breast – volume: 348 start-page: 618 year: 2003 end-page: 629 article-title: Selective estrogen‐receptor modulators: Mechanisms of action and application to clinical practice publication-title: N Engl J Med – volume: 295 start-page: 2727 year: 2006 end-page: 2741 article-title: Effect of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P‐2 trial publication-title: JAMA – volume: 59 start-page: 680 year: 1982 end-page: 686 article-title: Origin of serum estradiol in postmenopausal women publication-title: Obstet Gynecol – volume: 11 start-page: 2809 year: 2005 end-page: 2818 article-title: Aromatase inhibition: Translation into a successful therapeutic approach publication-title: Clin Cancer Res – volume: 24 start-page: 511 issue: Suppl 18S year: 2006 article-title: Effect of anastrozole on bone mineral density: 5‐year results from the arimidex, tamoxifen, alone or in combination ATAC trial publication-title: J Clin Oncol – volume: 3 start-page: 1101 year: 1997 end-page: 1108 article-title: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study publication-title: Clin Cancer Res – volume: 94 start-page: S233 issue: Suppl 1 year: 2005 article-title: Skeletal effect of exemestane in the Intergroup Exemestane Study (IES): 2 year bone mineral density (BMD) and bone biomarker data publication-title: Breast Cancer Res Treat – volume: 18 start-page: 16 issue: Suppl 2 year: 2004 end-page: 20 article-title: Hormone‐ and chemotherapy induced bone loss in breast cancer publication-title: Oncology – volume: 17 start-page: 652 year: 2003 end-page: 659 article-title: Long‐term toxicity of selective estrogen‐receptor modulators and antiaromatase agents publication-title: Oncology – volume: 5 start-page: S35 issue: Suppl 2 year: 2005 end-page: S40 article-title: Bone health in women with early‐stage breast cancer publication-title: Clin Breast Cancer – volume: 91 start-page: 3941 year: 2006 end-page: 3946 article-title: Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer publication-title: J Clin Endocrinol Metab – volume: 35 start-page: 25 year: 2000 end-page: 30 article-title: The effects of physical exercise on body fat distribution and bone mineral density in postmenopausal women publication-title: Maturitas – volume: 31 start-page: 23 year: 2004 end-page: 30 article-title: Optimizing bisphosphonate therapy in patients with breast cancer endocrine therapy publication-title: Semin Oncol – volume: 5 start-page: S63 issue: Suppl 2 year: 2005 end-page: S70 article-title: Strategies to prevent chemotherapy‐induced bone loss in women with breast cancer publication-title: Clin Breast Cancer – volume: 1 start-page: S9 issue: Suppl year: 2000 end-page: S14 article-title: Antiaromatase agents: Preclinical data and neoadjuvant therapy publication-title: Clin Breast Cancer – volume: 42 start-page: 2968 year: 2006 end-page: 2975 article-title: Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2‐year treatment with exemestane: A randomized, placebo‐controlled study publication-title: Eur J Cancer – volume: 5 start-page: S35 year: 2005 end-page: S40 article-title: Bone health in women with early‐stage breast cancer publication-title: Clin Breast Cancer – volume: 25 start-page: 820 year: 2007 end-page: 828 article-title: Zoledronic acid prevents cancer treatment‐induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone‐responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group publication-title: J Clin Oncol – volume: 5 start-page: S41 issue: Suppl 2 year: 2005 end-page: S45 article-title: Evaluating bone mass and bone quality in patients with breast cancer publication-title: Clin Breast Cancer – volume: 23 start-page: 5126 year: 2005 end-page: 5137 article-title: Effect of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarker, and plasma lipids in patients with surgically resected early breast cancer publication-title: J Clin Oncol – volume: 98 start-page: 1802 year: 2003 end-page: 1810 article-title: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone, or in Combination) trial efficacy and safety update analysis publication-title: Cancer – volume: 69 start-page: 220 year: 1998 end-page: 225 article-title: Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma publication-title: Gynecol Oncol – volume: 33 start-page: 13 issue: 2 year: 2006 end-page: 17 article-title: Management of cancer‐treatment‐induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z‐FAST update publication-title: Semin Oncol – volume: 90 start-page: 12 year: 1997 end-page: 15 article-title: Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents publication-title: Obstet Gynecol – volume: 42 start-page: 1044 year: 2006 end-page: 1051 article-title: Effect of third‐generation aromatase inhibitors on bone publication-title: Eur J Cancer – volume: 3 start-page: 1101 year: 1997 ident: e_1_2_5_11_2 article-title: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study publication-title: Clin Cancer Res – ident: e_1_2_5_21_2 doi: 10.3816/CBC.2005.s.002 – ident: e_1_2_5_10_2 doi: 10.1016/S0029-7844(97)00124-5 – volume: 94 start-page: S233 issue: 1 year: 2005 ident: e_1_2_5_15_2 article-title: Skeletal effect of exemestane in the Intergroup Exemestane Study (IES): 2 year bone mineral density (BMD) and bone biomarker data publication-title: Breast Cancer Res Treat – ident: e_1_2_5_25_2 doi: 10.1001/jama.295.23.joc60074 – ident: e_1_2_5_6_2 doi: 10.3816/CBC.2005.s.002 – ident: e_1_2_5_13_2 doi: 10.1002/cncr.11745 – volume: 24 start-page: 511 issue: 18 year: 2006 ident: e_1_2_5_8_2 article-title: Effect of anastrozole on bone mineral density: 5‐year results from the arimidex, tamoxifen, alone or in combination ATAC trial publication-title: J Clin Oncol doi: 10.1200/jco.2006.24.18_suppl.511 – volume: 18 start-page: 16 issue: 2 year: 2004 ident: e_1_2_5_5_2 article-title: Hormone‐ and chemotherapy induced bone loss in breast cancer publication-title: Oncology – ident: e_1_2_5_16_2 doi: 10.1158/1078-0432.CCR-04-2187 – ident: e_1_2_5_14_2 doi: 10.1053/j.seminoncol.2006.03.022 – ident: e_1_2_5_18_2 doi: 10.1016/j.ejca.2006.07.005 – ident: e_1_2_5_12_2 doi: 10.3816/CBC.2000.s.002 – ident: e_1_2_5_4_2 doi: 10.3816/CBC.2005.s.006 – ident: e_1_2_5_7_2 doi: 10.1200/JCO.2005.07.097 – ident: e_1_2_5_22_2 doi: 10.1053/j.seminoncol.2004.09.023 – ident: e_1_2_5_24_2 doi: 10.1056/NEJMra022219 – ident: e_1_2_5_2_2 doi: 10.1016/j.ejca.2005.10.028 – volume: 59 start-page: 680 year: 1982 ident: e_1_2_5_19_2 article-title: Origin of serum estradiol in postmenopausal women publication-title: Obstet Gynecol – ident: e_1_2_5_3_2 doi: 10.3816/CBC.2005.s.003 – ident: e_1_2_5_27_2 doi: 10.1016/S0378-5122(00)00094-3 – ident: e_1_2_5_9_2 doi: 10.1006/gyno.1998.5023 – volume: 17 start-page: 652 year: 2003 ident: e_1_2_5_17_2 article-title: Long‐term toxicity of selective estrogen‐receptor modulators and antiaromatase agents publication-title: Oncology – ident: e_1_2_5_23_2 doi: 10.1200/JCO.2005.02.7102 – ident: e_1_2_5_20_2 doi: 10.1016/j.breast.2004.09.005 – ident: e_1_2_5_26_2 doi: 10.1210/jc.2005-2827 |
| SSID | ssj0017918 |
| Score | 1.8009512 |
| Snippet | Aim: To investigate aromatase inhibitor‐induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer... Aim: To investigate aromatase inhibitor‐induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer... To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.... Aim: To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.... To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.AIMTo... |
| SourceID | proquest pubmed crossref wiley nii istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 696 |
| SubjectTerms | Aged aromatase inhibitor Aromatase Inhibitors - adverse effects Aromatase Inhibitors - therapeutic use bisphosphonate Bone Density - drug effects Bone Density Conservation Agents - therapeutic use bone mineral density Breast Neoplasms - drug therapy Drug Interactions Etidronic Acid - analogs & derivatives Etidronic Acid - therapeutic use Female Humans Middle Aged Nitriles - adverse effects Nitriles - therapeutic use Osteoporosis - chemically induced Osteoporosis - pathology Osteoporosis - prevention & control postmenopausal breast cancer patient Postmenopause Risedronate Sodium Triazoles - adverse effects Triazoles - therapeutic use |
| Title | Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients |
| URI | https://api.istex.fr/ark:/67375/WNG-FZ094FHF-X/fulltext.pdf https://cir.nii.ac.jp/crid/1570854175468590848 https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1447-0756.2007.00634.x https://www.ncbi.nlm.nih.gov/pubmed/17845332 https://www.proquest.com/docview/20589587 https://www.proquest.com/docview/68261916 |
| Volume | 33 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5BkRCX8i4uFPaAuDnyY3dtHyvAjSpRJERFxMXal1UrxY5sRyqc-gM49Df2lzCzdgKpilQhDomiKLv2bL6d_WZn_C0hr6NMy1Qy6SvJI59paX2prfQzVXIbGCmEddUWR2J6zA5nfDbWP-GzMIM-xHrDDWeG89c4waXqrkxyhttsXKyUCEXMJsgnw1igjP67T2slKRThdE_FgdNG_V2xWdRzbUcbK9UdHHT46nZdVdeR0U1u6xan_D6Zr8waalLmk2WvJvrHFcXH_2P3A7I9cli6P4DuIbll60fk7ocxS_-Y_NxvGyDCsD7Sqj6pFDiN9vL8AqJ_wJGhqqkt_VY5uWt6CqZTWRta9R1djHpSTU3Vd6qqbnHS4KsGQkzlhswv9EwXTYc18hD2LzvoSmF9fU814rilo2Bs94Qc5-8_v53646kPvgZqw3wRaR7YUAkLVIKFQSnjILMhppRLm4Yo719ibjQpA2NVBD7EZKHOtI6ZSUqgf0_JVg2GPCNUGZkFcSa0BNpnMp6WytpUA26tAaZoPJKs_uFCj5LoeDLHafFnaMSSAgcbD-zEXD0MdnHmkXDdcjHIgtygzRsHonUD2c6xrC7hxZejgyL_CpF2Ps2LmUf2AGVwR_ge8iTAcUg4EykeUM9Sj7xa4a8AZ4AZHlnbZtnB5XgKZiZ__4VIMWQOhUd2BuD-vv0kZcD9I49wB78b21UcfjyAD7v_2O45uef2y12B5Auy1bdLuwdEr1cv3RT-BbLHROc |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5BKwEX3g8DpXtA3BzZzu7aPlaAG0obJNSKiMtqX1atBjuyHQk48QM48Bv5JczYTiBVkSrEwZEVZdc7m9nZb3bG3xDyPEqNShRTvlY88plRzlfGKT_VOXeBVUK4LttiKiYn7GDGZ0M5IHwXpueHWB-44cro7DUucDyQPrfKGZ6zcbGiIhRjNgJAuc0Ad6An9ur9mksKaTi79-LAbCMDr9hM67mwp429ahunHb66WhbFRXB0E91221N2i8xXgvVZKWejZatH5us5zsf_JPltcnOAsXSv17s75Ior75JrR0Og_h75vldXgIVhi6RFeVposBv1z28_itKCKlmqq9LRT0XHeE3nIDtVpaVF29DFQClVlVR_obpoFqcVXiVgYqo2mH6hZ7qoGkyTB89_2UBXGlPsW2pQlWs6cMY298lJ9vr45cQfCj_4BtAN80VkeOBCLRygCRYGuRoHqQsxqpy7JESG_xzDo3EeWKcjMCM2DU1qzJjZOAcE-IBslSDII0K1VWkwToVRgPxsypNcO5cYUF1nASxaj8Srv1iagRUdi3PM5Z_eEYslTjbW7MRwPUy2_OyRcN1y0TODXKLNi06L1g1UfYaZdTGXH6b7MvsIznY2yeTMIzugZjAi_Ax5HOA8xJyJBGvUs8QjuysFlGAPMMijSlctG3gcT0DM-O-_EAl6zaHwyMNec38PP04YwP_II7zTv0vLJQ_e7cPN439st0uuT46PDuXhm-nbJ-RGd3ze5Us-JVttvXQ7gPta_axbz78AAbdJBg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9NAEF1BK1VcKN-4ULoHxM2R7eyu7WMFuKFAQIiKiIu1X1atFNuyEwk48QM48Bv5JcysnUCqIlWIQ6Ioyq49m7ezb3bGbwl5HKVaJpJJX0ke-UxL60ttpZ-qgtvASCGsq7aYiskJO57x2VD_hM_C9PoQ6w03nBnOX-MEb0xxbpIz3GbjYqVEKMZsBHxymwkgFkiQ3q2lpFCF0z0WB14bBXjFZlXPhT1tLFXbOOrw1dWqLC9io5vk1q1O2S6Zr-zqi1Lmo-VCjfTXc5KP_8fwG-T6QGLpYY-6m-SKrW6RnddDmv42-X7Y1sCEYYGkZXVaKvAa7c9vPyD8ByAZqurK0k-l07umZ2A6lZWh5aKjzSAoVVdUfaGq7JrTGl8VMGIqN3R-oWfa1B0WyUPcv-ygK4UF9guqEcgtHRRjuzvkJHv-_unEH4598DVwG-aLSPPAhkpY4BIsDAo5DlIbYk65sEmI-v4FJkfjIjBWReBETBrqVOsxM3EB_O8u2arAkPuEKiPTYJwKLYH3mZQnhbI20QBca4AqGo_Eq38414MmOh7NcZb_GRuxOMfBxhM7MVkPg51_9ki4btn0uiCXaPPEgWjdQLZzrKuLef5hepRnHyHUziZZPvPIPqAM7gjfQx4HOA4xZyLBE-pZ4pGDFf5y8AaY4pGVrZcdXI4nYGb891-IBGPmUHjkXg_c37cfJwzIf-QR7uB3abvy4zdH8GHvH9sdkJ23z7L81Yvpywfkmts7d8WSD8nWol3afSB9C_XIzeZf2nNHtQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aromatase+inhibitor-induced+bone+mineral+loss+and+its+prevention+by+bisphosphonate+administration+in+postmenopausal+breast+cancer+patients&rft.jtitle=The+journal+of+obstetrics+and+gynaecology+research&rft.au=Yonehara%2C+Yukie&rft.au=Iwamoto%2C+Ichiro&rft.au=Kosha%2C+Shoichiro&rft.au=Rai%2C+Yoshiaki&rft.date=2007-10-01&rft.pub=Blackwell+Publishing+Asia&rft.issn=1341-8076&rft.eissn=1447-0756&rft.volume=33&rft.issue=5&rft.spage=696&rft.epage=699&rft_id=info:doi/10.1111%2Fj.1447-0756.2007.00634.x&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_FZ094FHF_X |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-8076&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-8076&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-8076&client=summon |